{"id":"talion-tab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting this enzyme, Talion Tab reduces the production of a certain substance in the body, which is associated with the progression of the disease it is intended to treat.","oneSentence":"Talion Tab is a small molecule that inhibits the activity of a specific enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:56.223Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01840605","phase":"PHASE3","title":"A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2013-03","conditions":"Dermatitis, Atopic","enrollment":303},{"nctId":"NCT01861522","phase":"PHASE3","title":"The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2013-04","conditions":"Perennial Allergic Rhinitis","enrollment":473},{"nctId":"NCT01900054","phase":"PHASE3","title":"A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2013-06","conditions":"Perennial Allergic Rhinitis","enrollment":58},{"nctId":"NCT03317301","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2017-05-17","conditions":"Pruritus","enrollment":189},{"nctId":"NCT02686294","phase":"PHASE1","title":"Repeated Dosing Clinical Trial of HL151","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2016-02-16","conditions":"Rhinitis, Allergic, Perennial","enrollment":30},{"nctId":"NCT02682745","phase":"PHASE1","title":"Single Dosing Clinical Trial of HL151","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2016-01-15","conditions":"Rhinitis, Allergic, Perennial","enrollment":30},{"nctId":"NCT02332044","phase":"PHASE1","title":"Drug Interaction Study Between Erdosteine and Bepotastine Besilate in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2014-04","conditions":"Healthy","enrollment":36},{"nctId":"NCT01925313","phase":"PHASE1","title":"A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2012-12","conditions":"Healthy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Talion Tab","genericName":"Talion Tab","companyName":"Hanlim Pharm. Co., Ltd.","companyId":"hanlim-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Talion Tab is a small molecule that inhibits the activity of a specific enzyme. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}